Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.16 USD | +0.57% | -8.84% | -39.56% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.56% | 2.03B | B- | ||
-2.70% | 187B | C+ | ||
-1.67% | 106B | C | ||
-4.44% | 66.9B | A | ||
+0.78% | 49.45B | B- | ||
+16.55% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+3.61% | 26.48B | B | ||
+1.27% | 26.25B | A- | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CNMD Stock
- Ratings CONMED Corporation